HTML Microdata document

This HTML5 document contains 95 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
n2	http://linked.opendata.cz/resource/drugbank/drug/
dcterms	http://purl.org/dc/terms/
n25	http://linked.opendata.cz/resource/AHFS/
foaf	http://xmlns.com/foaf/0.1/
n27	http://linked.opendata.cz/resource/mesh/concept/
n4	http://linked.opendata.cz/resource/drugbank/company/
n13	http://linked.opendata.cz/resource/drugbank/drug/DB01413/identifier/national-drug-code-directory/
n28	http://linked.opendata.cz/resource/drugbank/dosage/
n9	http://linked.opendata.cz/resource/drugbank/drug/DB01413/identifier/chemspider/
n29	http://bio2rdf.org/drugbank:
n14	http://linked.opendata.cz/resource/drugbank/drug/DB01413/identifier/chebi/
adms	http://www.w3.org/ns/adms#
n24	http://www.rxlist.com/cgi/generic/
n16	http://linked.opendata.cz/resource/drugbank/drug/DB01413/identifier/wikipedia/
n18	http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n15	http://linked.opendata.cz/resource/drugbank/drug/DB01413/identifier/pharmgkb/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n19	http://linked.opendata.cz/resource/drugbank/medicinal-product/
owl	http://www.w3.org/2002/07/owl#
n26	http://linked.opendata.cz/ontology/mesh/
n3	http://linked.opendata.cz/ontology/drugbank/
n23	http://www.drugs.com/cdi/
n8	http://linked.opendata.cz/resource/drugbank/drug/DB01413/identifier/kegg-compound/
n11	http://linked.opendata.cz/resource/drugbank/drug/DB01413/identifier/pubchem-compound/
n5	http://linked.opendata.cz/resource/drugbank/property/
xsdh	http://www.w3.org/2001/XMLSchema#
n30	http://linked.opendata.cz/resource/drugbank/drug/DB01413/identifier/pubchem-substance/
n12	http://linked.opendata.cz/resource/drugbank/drug/DB01413/identifier/kegg-drug/
n20	http://linked.opendata.cz/ontology/sukl/drug/
n21	http://linked.opendata.cz/resource/atc/
n10	http://linked.opendata.cz/resource/drugbank/drug/DB01413/identifier/drugbank/

Statements

Subject Item: n2:DB01413
rdf:type: n3:Drug
n3:description: Cefepime is a fourth-generation cephalosporin antibiotic developed in 1994. Cefepime has an extended spectrum of activity against Gram-positive and Gram-negative bacteria, with greater activity against both Gram-negative and Gram-positive organisms than third-generation agents. Cefepime is usually reserved to treat severe nosocomial pneumonia, infections caused by multi-resistant microorganisms (e.g. Pseudomonas aeruginosa) and empirical treatment of febrile neutropenia.
n3:dosage: n28:271B47E9-363D-11E5-9242-09173F13E4C5 n28:271B47EA-363D-11E5-9242-09173F13E4C5 n28:271B47E5-363D-11E5-9242-09173F13E4C5 n28:271B47E6-363D-11E5-9242-09173F13E4C5 n28:271B47E7-363D-11E5-9242-09173F13E4C5 n28:271B47E8-363D-11E5-9242-09173F13E4C5 n28:271B47E1-363D-11E5-9242-09173F13E4C5 n28:271B47E2-363D-11E5-9242-09173F13E4C5 n28:271B47E3-363D-11E5-9242-09173F13E4C5 n28:271B47E4-363D-11E5-9242-09173F13E4C5
n3:generalReferences: # Chapman TM, Perry CM: Cefepime: a review of its use in the management of hospitalized patients with pneumonia. Am J Respir Med. 2003;2(1):75-107. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14720024
n3:group: approved
n3:halfLife: 2.0 (± 0.3) hours in normal patients. The average half-life in patients requiring hemodialysis was 13.5 (± 2.7) hours and in patients requiring continuous peritoneal dialysis was 19.0 (± 2.0) hours.
n3:indication: For the treatment of pneumonia (moderate to severe) caused by Streptococcus pneumoniae, including cases associated with concurrent bacteremia, Pseudomonas aeruginosa, Klebsiella pneumoniae, or Enterobacter species. Also for empiric treatment of febrile neutropenic patients and uncomplicated and complicated urinary tract infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae, when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis, when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. Also for the treatment of uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible strains only) or Streptococcus pyogenes and complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter species, or Bacteroides fragilis.
owl:sameAs: n18:DB01413 n29:DB01413
dcterms:title: Cefepime
adms:identifier: n8:C08111 n9:4586395 n10:DB01413 n11:5479537 n12:D02376 n13:0338-1301-41 n14:478164 n15:PA164754876 n16:Cefepime n30:46507919
n3:mechanismOfAction: Cephalosporins are bactericidal and have the same mode of action as other beta-lactam antibiotics (such as penicillins). Cephalosporins disrupt the synthesis of the peptidoglycan layer of bacterial cell walls. The peptidoglycan layer is important for cell wall structural integrity, especially in Gram-positive organisms. The final transpeptidation step in the synthesis of the peptidoglycan is facilitated by transpeptidases known as penicillin binding proteins (PBPs).
n3:packager: n4:271B47CE-363D-11E5-9242-09173F13E4C5 n4:271B47D4-363D-11E5-9242-09173F13E4C5 n4:271B47D5-363D-11E5-9242-09173F13E4C5 n4:271B47D2-363D-11E5-9242-09173F13E4C5 n4:271B47D3-363D-11E5-9242-09173F13E4C5 n4:271B47D0-363D-11E5-9242-09173F13E4C5 n4:271B47D1-363D-11E5-9242-09173F13E4C5 n4:271B47DA-363D-11E5-9242-09173F13E4C5 n4:271B47D8-363D-11E5-9242-09173F13E4C5 n4:271B47D9-363D-11E5-9242-09173F13E4C5 n4:271B47D6-363D-11E5-9242-09173F13E4C5 n4:271B47D7-363D-11E5-9242-09173F13E4C5 n4:271B47CF-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination: Elimination of cefepime is principally via renal excretion with an average (±SD) half-life of 2 (±0.3) hours and total body clearance of 120 (±8) mL/min in healthy volunteers. Cefepime is excreted in human milk.
n3:synonym: (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-[(1-methylpyrrolidinium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Cefepime Cefepima Cefepimum
n3:toxicity: Symptoms of overdose include seizures, encephalopathy, and neuromuscular excitability.
n3:volumeOfDistribution: * 18.0 ±2.0 L * 0.3 ±0.1 L/kg [Pediatric]
n20:hasAHFSCode: n25:08-12-06-16
n3:proteinBinding: The serum protein binding of cefepime is approximately 20% and is independent of its concentration in serum.
n3:salt
n3:synthesisReference: Vijay Handa, Anand Kamat, Meenakshisunderam Sivakumaran, "Process for preparing cefepime." U.S. Patent US20050043531, issued February 24, 2005.
n26:hasConcept: n27:M0127410
foaf:page: n23:cefepime.html n24:cefep.htm
n3:IUPAC-Name: n5:271B47EF-363D-11E5-9242-09173F13E4C5
n3:InChI: n5:271B47F5-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula: n5:271B47F4-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight: n5:271B47F1-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight: n5:271B47F2-363D-11E5-9242-09173F13E4C5
n3:SMILES: n5:271B47F3-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility: n5:271B47ED-363D-11E5-9242-09173F13E4C5
n3:logP: n5:271B47EE-363D-11E5-9242-09173F13E4C5 n5:271B47EB-363D-11E5-9242-09173F13E4C5
n3:logS: n5:271B47EC-363D-11E5-9242-09173F13E4C5
n20:hasATCCode: n21:J01DE01
n3:H-Bond-Acceptor-Count: n5:271B47FB-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count: n5:271B47FC-363D-11E5-9242-09173F13E4C5
n3:InChIKey: n5:271B47F6-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-: n5:271B47F7-363D-11E5-9242-09173F13E4C5
n3:Polarizability: n5:271B47F9-363D-11E5-9242-09173F13E4C5
n3:Refractivity: n5:271B47F8-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count: n5:271B47FA-363D-11E5-9242-09173F13E4C5
n3:absorption: The absolute bioavailability of cefepime after an IM dose of 50 mg/kg was 82.3 (±15)% in eight patients.
n3:affectedOrganism: Enteric bacteria and other eubacteria
n3:casRegistryNumber: 88040-23-7
n3:category
n3:clearance: * 120 mL/min [Healthy adult male receiving a single 30-minute IV infusions of cefepime] * 3.3 +/-1.0 mL/min/kg [Petriatic patients (2 months – 11 years of age) receiving a single IV dose]
n3:containedIn: n19:271B47DD-363D-11E5-9242-09173F13E4C5 n19:271B47DE-363D-11E5-9242-09173F13E4C5 n19:271B47DB-363D-11E5-9242-09173F13E4C5 n19:271B47DC-363D-11E5-9242-09173F13E4C5 n19:271B47DF-363D-11E5-9242-09173F13E4C5 n19:271B47E0-363D-11E5-9242-09173F13E4C5
n3:Bioavailability: n5:271B4801-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter: n5:271B4803-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule: n5:271B4804-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings: n5:271B4800-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge: n5:271B47FF-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five: n5:271B4802-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name: n5:271B47F0-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-: n5:271B47FD-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-: n5:271B47FE-363D-11E5-9242-09173F13E4C5